IL115589A0 - Use of cck-b antagonists in pharmaceutical compositions - Google Patents

Use of cck-b antagonists in pharmaceutical compositions

Info

Publication number
IL115589A0
IL115589A0 IL11558995A IL11558995A IL115589A0 IL 115589 A0 IL115589 A0 IL 115589A0 IL 11558995 A IL11558995 A IL 11558995A IL 11558995 A IL11558995 A IL 11558995A IL 115589 A0 IL115589 A0 IL 115589A0
Authority
IL
Israel
Prior art keywords
cck
antagonists
pharmaceutical compositions
treatment
sleep disorders
Prior art date
Application number
IL11558995A
Other languages
English (en)
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420703A external-priority patent/GB9420703D0/en
Priority claimed from GB9420704A external-priority patent/GB9420704D0/en
Priority claimed from GB9423098A external-priority patent/GB9423098D0/en
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of IL115589A0 publication Critical patent/IL115589A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11558995A 1994-10-14 1995-10-12 Use of cck-b antagonists in pharmaceutical compositions IL115589A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420703A GB9420703D0 (en) 1994-10-14 1994-10-14 Medicament
GB9420704A GB9420704D0 (en) 1994-10-14 1994-10-14 Medicaments
GB9423098A GB9423098D0 (en) 1994-11-16 1994-11-16 Medicaments

Publications (1)

Publication Number Publication Date
IL115589A0 true IL115589A0 (en) 1996-01-19

Family

ID=27267429

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11558995A IL115589A0 (en) 1994-10-14 1995-10-12 Use of cck-b antagonists in pharmaceutical compositions

Country Status (9)

Country Link
US (1) US6413930B1 (de)
EP (1) EP0785788B1 (de)
JP (1) JPH10511928A (de)
AT (1) ATE210447T1 (de)
AU (1) AU3745795A (de)
DE (1) DE69524623T2 (de)
ES (1) ES2171196T3 (de)
IL (1) IL115589A0 (de)
WO (1) WO1996011689A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715611B2 (en) 1995-12-11 2000-02-03 New England Medical Center Hospitals, Inc., The Assay for and uses of peptide hormone receptor ligands
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
AU3591697A (en) * 1996-07-02 1998-01-21 Merck & Co., Inc. Method for the treatment of preterm labor
US5929071A (en) * 1996-07-02 1999-07-27 Merck & Co., Inc. Method for the treatment of preterm labor
EP1392262A1 (de) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Verabreichung von arzneimittel-estern durch inhalation
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0310864D0 (en) * 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
US20050079166A1 (en) 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2121088B1 (de) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
DE69319945T2 (de) * 1992-01-21 1999-03-11 Glaxo Wellcome S.P.A., Verona 1,5-Benzodiazepinderivate und deren Verwendung in Heilmittel
TW213901B (de) * 1992-01-27 1993-10-01 Pfizer

Also Published As

Publication number Publication date
DE69524623T2 (de) 2002-08-08
WO1996011689A1 (en) 1996-04-25
JPH10511928A (ja) 1998-11-17
ES2171196T3 (es) 2002-09-01
DE69524623D1 (de) 2002-01-24
EP0785788A1 (de) 1997-07-30
ATE210447T1 (de) 2001-12-15
AU3745795A (en) 1996-05-06
EP0785788B1 (de) 2001-12-12
US6413930B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
AP2000001785A0 (en) Medicaments
HUP9800792A3 (en) Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same
HK1020522A1 (en) Novel formulation
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
IL112895A (en) Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
BG105256A (en) Muscarinic agonists and antagonists
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions